Assurex Health (Myriad Neuroscience)
Genetic testing company providing pharmacogenomic testing services to guide medication selection for mental health conditions, now operating as Myriad Neuroscience.
Notes
Assurex Health was a pioneering genetic testing company focused on pharmacogenomics for mental health medications. The company developed the GeneSight test, a pharmacogenomic test that analyzes how a patient's genes may affect their response to medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions.
In 2016, Assurex Health was acquired by Myriad Genetics and now operates as Myriad Neuroscience. The GeneSight test continues to be widely used to help clinicians personalize medication selection for patients with mental health conditions, reducing trial-and-error prescribing.
The company was backed by Sequoia Capital and other leading investors before its acquisition.
Team
- Don Wright, Ph.D. - Former Chief Executive Officer (Assurex Health)
- James Burns - President, Myriad Neuroscience
- LinkedIn: linkedin.com/in/jamesburns
Additional Research Findings
- Acquired by Myriad Genetics in 2016
- Now operates as Myriad Neuroscience
- GeneSight pharmacogenomic test for mental health medications
- Portfolio company of Sequoia Capital (pre-acquisition)
- Focus on precision medicine for psychiatry
- Mason, Ohio headquarters
- Helps personalize psychiatric medication selection
- Founded 2006
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sequoia Capital | Menlo Park, California, USA | generalist | seedseries-a+3 | 4 |